1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Partner Fund Management, L.P. Buys Allergan PLC, Biomarin Pharmaceutical Inc, Gilead Sciences Inc, Sells UnitedHealth Group Inc, Blueprint Medicines Corp, Arena Pharmaceuticals Inc

San Francisco, CA, based Investment company Partner Fund Management, L.P. (Current Portfolio) buys Allergan PLC, Biomarin Pharmaceutical Inc, Gilead Sciences Inc, Sarepta Therapeutics Inc, Alibaba Group Holding, sells UnitedHealth Group Inc, Blueprint Medicines Corp, Arena Pharmaceuticals Inc, Pfizer Inc, Anthem Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Partner Fund Management, L.P.. As of 2019Q2, Partner Fund Management, L.P. owns 75 stocks with a total value of $4.1 billion. These are the details of the buys and sells.

For the details of Partner Fund Management, L.P.'s stock buys and sells, go to https://www.gurufocus.com/guru/partner+fund+management%2C+l.p./current-portfolio/portfolio

These are the top 5 holdings of Partner Fund Management, L.P.
  1. Allergan PLC (AGN) - 1,785,597 shares, 7.35% of the total portfolio. Shares added by 210.63%
  2. Biomarin Pharmaceutical Inc (BMRN) - 2,079,388 shares, 4.38% of the total portfolio. New Position
  3. Humana Inc (HUM) - 562,177 shares, 3.67% of the total portfolio. Shares added by 54.24%
  4. Zimmer Biomet Holdings Inc (ZBH) - 1,165,494 shares, 3.37% of the total portfolio. Shares added by 22.52%
  5. WellCare Health Plans Inc (WCG) - 480,244 shares, 3.37% of the total portfolio. Shares added by 44.29%
New Purchase: Biomarin Pharmaceutical Inc (BMRN)

Partner Fund Management, L.P. initiated holding in Biomarin Pharmaceutical Inc. The purchase prices were between $80.35 and $93.9, with an estimated average price of $85.56. The stock is now traded at around $76.11. The impact to a portfolio due to this purchase was 4.38%. The holding were 2,079,388 shares as of .

New Purchase: Gilead Sciences Inc (GILD)

Partner Fund Management, L.P. initiated holding in Gilead Sciences Inc. The purchase prices were between $61.87 and $69.38, with an estimated average price of $65.76. The stock is now traded at around $63.55. The impact to a portfolio due to this purchase was 2.27%. The holding were 1,364,288 shares as of .

New Purchase: Sarepta Therapeutics Inc (SRPT)

Partner Fund Management, L.P. initiated holding in Sarepta Therapeutics Inc. The purchase prices were between $112.21 and $151.95, with an estimated average price of $121.45. The stock is now traded at around $99.56. The impact to a portfolio due to this purchase was 2.04%. The holding were 546,786 shares as of .

New Purchase: DexCom Inc (DXCM)

Partner Fund Management, L.P. initiated holding in DexCom Inc. The purchase prices were between $111.38 and $155.66, with an estimated average price of $125.45. The stock is now traded at around $168.86. The impact to a portfolio due to this purchase was 1.52%. The holding were 411,696 shares as of .

New Purchase: The Walt Disney Co (DIS)

Partner Fund Management, L.P. initiated holding in The Walt Disney Co. The purchase prices were between $111.96 and $142.02, with an estimated average price of $132.62. The stock is now traded at around $135.65. The impact to a portfolio due to this purchase was 1.37%. The holding were 398,702 shares as of .

New Purchase: Progressive Corp (PGR)

Partner Fund Management, L.P. initiated holding in Progressive Corp. The purchase prices were between $71.53 and $83.34, with an estimated average price of $77.36. The stock is now traded at around $76.85. The impact to a portfolio due to this purchase was 1.28%. The holding were 653,485 shares as of .

Added: Allergan PLC (AGN)

Partner Fund Management, L.P. added to a holding in Allergan PLC by 210.63%. The purchase prices were between $115.73 and $167.43, with an estimated average price of $138.45. The stock is now traded at around $159.81. The impact to a portfolio due to this purchase was 4.98%. The holding were 1,785,597 shares as of .

Added: Alibaba Group Holding Ltd (BABA)

Partner Fund Management, L.P. added to a holding in Alibaba Group Holding Ltd by 213.58%. The purchase prices were between $149.26 and $195.21, with an estimated average price of $172.54. The stock is now traded at around $177.03. The impact to a portfolio due to this purchase was 1.62%. The holding were 571,376 shares as of .

Added: Salesforce.com Inc (CRM)

Partner Fund Management, L.P. added to a holding in Salesforce.com Inc by 191.51%. The purchase prices were between $145.1 and $165.96, with an estimated average price of $156.67. The stock is now traded at around $145.64. The impact to a portfolio due to this purchase was 1.47%. The holding were 598,759 shares as of .

Added: IQVIA Holdings Inc (IQV)

Partner Fund Management, L.P. added to a holding in IQVIA Holdings Inc by 130.60%. The purchase prices were between $132.28 and $160.9, with an estimated average price of $140.12. The stock is now traded at around $155.05. The impact to a portfolio due to this purchase was 1.43%. The holding were 638,326 shares as of .

Added: Humana Inc (HUM)

Partner Fund Management, L.P. added to a holding in Humana Inc by 54.24%. The purchase prices were between $232.89 and $276.48, with an estimated average price of $253.55. The stock is now traded at around $295.60. The impact to a portfolio due to this purchase was 1.29%. The holding were 562,177 shares as of .

Added: HCA Healthcare Inc (HCA)

Partner Fund Management, L.P. added to a holding in HCA Healthcare Inc by 119.47%. The purchase prices were between $112.01 and $135.18, with an estimated average price of $126.22. The stock is now traded at around $122.87. The impact to a portfolio due to this purchase was 1.14%. The holding were 629,767 shares as of .

Sold Out: Blueprint Medicines Corp (BPMC)

Partner Fund Management, L.P. sold out a holding in Blueprint Medicines Corp. The sale prices were between $73.54 and $97.8, with an estimated average price of $82.43.

Sold Out: PTC Therapeutics Inc (PTCT)

Partner Fund Management, L.P. sold out a holding in PTC Therapeutics Inc. The sale prices were between $35.42 and $45, with an estimated average price of $39.44.

Sold Out: Amazon.com Inc (AMZN)

Partner Fund Management, L.P. sold out a holding in Amazon.com Inc. The sale prices were between $1692.69 and $1962.46, with an estimated average price of $1862.37.

Sold Out: WAVE Life Sciences Ltd (WVE)

Partner Fund Management, L.P. sold out a holding in WAVE Life Sciences Ltd. The sale prices were between $22.93 and $42.84, with an estimated average price of $27.96.

Sold Out: Live Nation Entertainment Inc (LYV)

Partner Fund Management, L.P. sold out a holding in Live Nation Entertainment Inc. The sale prices were between $60.07 and $67.22, with an estimated average price of $64.24.

Sold Out: NXP Semiconductors NV (NXPI)

Partner Fund Management, L.P. sold out a holding in NXP Semiconductors NV. The sale prices were between $88.16 and $108.08, with an estimated average price of $96.88.



Here is the complete portfolio of Partner Fund Management, L.P.. Also check out:

1. Partner Fund Management, L.P.'s Undervalued Stocks
2. Partner Fund Management, L.P.'s Top Growth Companies, and
3. Partner Fund Management, L.P.'s High Yield stocks
4. Stocks that Partner Fund Management, L.P. keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:



Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)